Prescribing anti‐tumor necrosis factor (TNF) agents (etanercept, infliximab, and adalimumab) in patients with vasculitis phenomena, including strokes, seems to be the cornerstone of DADA2 treatment and reduces levels of inflammatory markers [1, 3, 9, 15]. This evidence concerns the gene TNF and vasculitis.